COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04860297

Not reported

Not reported

2021-04-26

Completed

nonRCT

Non-randomized

Single group assignment

Open label

multi-center

Prevention

transplant recipients key inclusion criteria for part a: is either a kidney or a liver transplant recipient who is at least 90 days after transplantation at the time of consent, and is either unvaccinated or previously vaccinated with 2 doses of moderna covid-19 vaccine who is at least 1 month after the second dose at the time of consent. participants who received the 2 doses of moderna covid-19 vaccine before transplant are not eligible. understands, agrees, and is able to comply with the study procedures and provides written informed consent. received chronic immunosuppressive therapy for the prevention of allograft rejection for a minimum of 90 days before signing consent, including but not limited to: glucocorticoids (such as, prednisolone), immunophilin binding agents (such as, calcineurin inhibitors, mtor inhibitors), or inhibitors of de novo nucleotide synthesis (such as, mycophenolic acid, mizoribine, leflunomide, azathioprine). for female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection, agreement to continue adequate contraception or abstinence through 3 months following the second dose (day 29) for those receiving 2-dose regimen and, through 3 months following the third dose (day 85) for those receiving 3-dose regimen, and through 3 months following the third dose (day 1) for those previously vaccinated sot participants, and not currently breastfeeding. is medically stable, according to investigator's judgment, during the 3 months before signing consent. key exclusion criteria for part a: has prior or planned administration of a coronavirus vaccine (for example, sars-cov-2 [for unvaccinated participants only], sars-cov, or mers [middle east respiratory syndrome] -cov vaccine). has current treatment with investigational agents for either prophylaxis against covid-19 (for unvaccinated participants only) or treatment of covid-19 (such as, anti-sars-cov-2 monoclonal antibodies). a history of more than one solid organ transplanted (such as, kidney and pancreas). a history of previous kidney or liver transplant is acceptable. has received therapies that have depleting properties on t cells, b cells, and plasma cells (examples of depletional therapies include, but are not limited to, antithymocyte globulin [atg], monoclonal antibodies, and proteosome inhibitors) within the last 3 months prior to enrollment. a history of biopsy-proven t-cell- or ab-mediated rejection within 3 months of informed consent, or suspected active or chronic rejection according to the investigator's judgment. has a known close contact with anyone with laboratory confirmed sars-cov-2 infection within 2 weeks to vaccine administration or known history of sars-cov-2 infection or positive sars-cov-2 test. has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the investigator's judgment. has a history of clinically relevant donor-specific ab. has a history of complications of immunosuppression suspected clinically relevant active hepatitis, including viral hepatitis, according to the investigator's judgment known human immunodeficiency virus (hiv) infection has a history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety. received any non-study vaccine within 28 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine) received intravenous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to day 1. participated in an interventional clinical study within 28 days prior to day 0 or plans to donate blood products while participating in this study. healthy participants key inclusion criteria for part a: in good general health without current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition, according to investigator assessment, at the time of consent, and has not been vaccinated with any covid-19 vaccine at the time of consent. understands, agrees, and is able to comply with the study procedures and provides written informed consent. for female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (day 1), agreement to continue adequate contraception or abstinence through 3 months following the second injection (day 29), and not currently breastfeeding. is medically stable, according to investigator's judgment, during the 3 months before signing consent. key exclusion criteria for part a: has a known close contact with anyone with laboratory confirmed sars-cov-2 infection or covid-19 within 2 weeks prior to vaccine administration or known history of sars-cov-2 infection or positive sars-cov-2 test. has prior or planned administration of a coronavirus vaccine (for example, sars-cov-2, sars-cov, or mers-cov vaccine). has current treatment with investigational agents for either prophylaxis against covid-19 or treatment of covid-19 (for example, anti-sars-cov-2 monoclonal antibodies). has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the investigator's judgment. has a history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety. received any non-study vaccine within 28 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine) received intravenous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to day 1. received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to screening (for corticosteroids ≥20 mg/day of prednisone equivalent). participated in an interventional clinical study within 28 days prior to day 0 or plans to donate blood products while participating in this study. inclusion criteria for part b: participants must have been previously enrolled in this study (mrna-1273-p304), are actively participating in part a, and at least 4 months from the last dose; or participant is either a kidney or a liver sot recipient who is at least 90 days after transplantation at the time of consent and who completed primary vaccination series (3 doses for mrna covid-19 vaccine; 2 doses for non-mrna covid-19 vaccine or at least 1 dose of non-mrna combined with 1 dose of mrna covid-19 vaccine) under the eua who are at least 4 months from the last dose. all primary covid-19 vaccination series must be completed after transplant. female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (booster dose day 1). exclusion criteria for part b: exclusion criteria in part a will apply except: prior or planned administration of a coronavirus vaccine and current treatment with investigational agents for either prophylaxis against covid-19. known close contact with anyone with laboratory-confirmed sars-cov-2 infection or covid-19 within 2 weeks prior to vaccine administration or any known history of sars-cov-2 infection or positive sarscov-2 test will apply only to new sot participants who will be enrolled in part b.

None

1

ModernaTX, Inc.

18

100

United States

High risk patients

N/A

234

Part A: Geometric Mean Concentration (GMC) of Serum SARS-CoV-2-Specific Neutralizing Antibody (nAb) After the Second Dose in Unvaccinated Participants;Part A: GMC of SARS-CoV-2-Specific nAb 28 Days After Dose 3;Part B: GMC of SARS-CoV-2-Specific nAb 28 Days After the BD in SOT Participants Who Received the Moderna Primary Series and Non-Moderna Primary Series;Parts A and B: Number of Healthy Participants With AESIs, Including Myocarditis/Pericarditis;Parts A and B: Number of Healthy Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal);Parts A and B: Number of Healthy Participants With Biopsy-Proven Organ Rejection;Parts A and B: Number of Healthy Participants With MAAEs;Parts A and B: Number of Healthy Participants With SAEs;Parts A and B: Number of Healthy Participants With Solicited Local and Systemic ARs;Parts A and B: Number of Healthy Participants With Unsolicited AEs;Parts A and B: Number of SOT Participants With Adjudicated Biopsy-Proven Organ Rejection;Parts A and B: Number of SOT Participants With Adverse Event of Special Interests (AESIs), Including Myocarditis/Pericarditis;Parts A and B: Number of SOT Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal);Parts A and B: Number of SOT Participants With Medically-Attended Adverse Events (MAAEs);Parts A and B: Number of SOT Participants With Serious Adverse Events (SAEs);Parts A and B: Number of SOT Participants With Solicited Local and Systemic Adverse Reactions (ARs);Parts A and B: Number of SOT Participants With Unsolicited Adverse Events (AEs)

None

Phase 3

[{"arm_notes": "100 ug;2;Days1-29;IM", "treatment_id": 824, "treatment_name": "Mrna-1273", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}]